Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Terns Enters $228 Million Agreement with Genfit for NASH Candidate

publication date: Jun 25, 2019

Terns Pharma, a California-Shanghai startup, acquired greater China rights to a treatment for liver disease developed by Genfit of France in an agreement worth up to $228 million. Elafibranor is a dual peroxisome proliferator-activated alpha/delta (PPAR α/δ ) agonist currently in US Phase III trials. Terns will have rights to develop elafibranor to treat non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC) in China. A liver disease and cancer company, Terns will make a $35 million upfront payment to Genfit, with the rest being regulatory and sales milestones. More details....

Share this with colleagues:


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Upcoming Events

ChinaBio® Partnering Forum
September 10–11, 2024 | Shanghai, China
Register here

BIO-Europe®
November 4–6, 2024 | Stockholm, Sweden
Save €900 before September 13!
Register here

Biotech Showcase™
January 13–15, 2025 | San Francisco, CA
Save $600 before September 27!
Other Relevant Events

Antibody Engineering & Therapeutics Asia
October 21–23, 2024 | Kyoto, Japan
Save 30% with code CHINABIO30!
Register here